Peter Harrison
Chief Executive officer
Bioventix continues to evolve from the generation of value from our historical product portfolio of core antibodies into a business with increasing expertise and reach in the creation of antibodies for application in the diagnosis of a range of neurological conditions and diseases.
A snapshot of some key figures from the year ending June 2026.
12
The composition of the Bioventix team remains at 12 full-time equivalents.
£257k
Tau / neuro royalties increased threefold from 2024/25
5 Tau antibodies
Being made at scale
£7.8M
Paid to shareholders in dividends
Financial year 2025/26
A significant scientific development during the year has been the emergence of “eMTBR-Tau” immunoassays from Alamar Biosciences and Spear Bio. Whilst p-Tau217 tracks AD through early amyloid pathology and later Tau tangle pathology, eMTBR-Tau is more specific for later stage disease caused by Tau tangles. eMTBR-Tau assays could therefore be useful to confirm clinical assessment of cognition in later stage disease. In addition, eMTBR-Tau could be helpful in ruling out candidates forclinical trials and future therapeutic options.
We believe we have made excellent eMTBR SMAs and are delighted to have played our part in the eMTBR-Tau discovery process.
The overall response from customers to our various Tau evaluation samples of SMAs supplied for RuO assays has been positive and we are encouraged by our growing footprint in these areas.
Our purpose at Bioventix is to create, manufacture and supply high affinity sheep monoclonal antibodies for use in diagnostic applications. The use of our products in In Vitro Diagnostic (“IVD”) tests allows clinicians to accurately and economically diagnose and then appropriately treat life changing diseases and conditions thereby improving outcomes and the lives of populations across the world.
Bioventix continues to evolve from the generation of value from our historical product portfolio of core antibodies into a business with increasing expertise and reach in the creation of antibodies for application in the diagnosis of a range of neurological conditions and diseases.
Looking Ahead
In addition, as the frontier of neuroscience and the blood-based biomarker field evolves, we will seek additional opportunities that may emerge from other collaborators in this rapidly developing area.